加科思-B2023年度报告

加 科 思 藥 業 集 團 有 限 公 司JACOBIO PHARMACEUTICALS GROUP CO., LTD.（於開曼群島註冊成立的有限公司）股份代號 :1167 245610344256120144148149150151152153208209 2023831 22 20233232023323 2920 20233232023323 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 20233232023323 1058 2023831202332320233232023831 24840 88 Walkers Corporate Limited 190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands http://www.jacobiopharma.com 1831717121716 1167 Cooley HK835 124 Bank of America41 Beacon streetFraminghamMA 01701USA 8-1020249 JAB-3312SHP2SHP2JAB-3312KRASG12C(NDA)JAB-331286.7%(13/15)BETAp53 20244 2023123163.5AbbVieSHP2 20221231445.673.316.4%20231231372.3 2022123142.64.09.4%2023123146.6 20221231371.920231231359.1 •JAB-21822glecirasib KRAS G12CJAB-3312SHP2 NSCLC ≥2LNSCLC-glecirasibKRASG12C≥2LNSCLC60202392024CMCNDA20239CDENDA20243Glecirasib≥2L NSCLCNDA2024CDE 1LNSCLCJAB-3312SHP2-glecirasibJAB-3312KRASG12CI/IIa1442023102023(ESMO)200KRASG12CglecirasibJAB-33121001L NSCLC2024(ASCO) GlecirasibJAB-33121LNSCLCPD-1+CDE20242glecirasibJAB-33121L NSCLCIIIIII2024JAB-3312IIISHP2 PDAC 20237g l e c i r a s i bK R A SG12C≥2LP D A CC D Egleciraisb≥2LKRASG12C202310GlecirasibIIIa202412024(ASCO)GIGlecirasib≥2L PDACFDA 20238glecirasibCDEKRASG12C 20244glecirasibFDA CRC glecirasibglecirasibcetuximabKRASG12CIIIGlecirasibcetuximabKRAS G12C20236(JCA)(AACR)GlecirasibglecirasibcetuximabIIICDE2024CDE KRASG12CglecirasibGlecirasibIIIa202412024(ASCO) GI •JAB-8263BET JAB-8263II2024JAB-8263BETJAB-8263(TSS)(SVR)JAB-82632024 •JAB-2485Aurora A JAB-2485I/IIa20231RP2D2024 JAB-2485202342023AACR2023AACR •JAB-30355P53 Y220C JAB-30355p53Y220CP53JAB-30355IND20243FDAJAB-30355CDEINDI2024 2024AACR •JAB-BX102CD73 I/IIaRP2D2024 •IND JAB-26766PARP7JAB-24114Glutamine-utilizingEnzyme JAB-BX300LIFINDJAB-26766JAB-24114JAB-BX300 JAB-267662024AACR2024452024410 IND •JAB-23E73KRASmulti JAB-23E73KRASmultiGTPGDPKRASHRASNRASKRAS2024JAB-23E73INDKRASKRASJAB-23E73 KRASmulti2023AACR iADC (iADC)(ICI)ICISTINGTAASTINGPD-1PD-1iADCHER2-STING iADC (JAB-BX400)CD73-STING iADC (JAB-BX500)JAB-BX400SK-OV-3JAB-BX4002024TAAiADC CD73-SING iADC2023AACR Kirsten2(KRAS)MYC(MYC)p53-1(PD-1)(PD-L1)(PTP)Src2-2(SHP2)GTPKRAS 20157iADC (MNC) NDAIND IND SHP2JAB-3312KRASglecirasibJAB-23E73SHP2KRAS G12CSHP2KRASG12CJAB-3312glecirasib1LNSCLCIII20242CDE20242023102023ESMO2024ASCO20246 2023glecirasib(JAB-21822)2024NDAKRASG12C≥2LNSCLCPDACglecirasibII1LNSCLCglecirasibJAB-3312KRAS G12C1L NSCLCIII20242CDEIII2024CRCglecirasibglecirasibcetuximab≥3LKRAS G12CCRCIIICDE2024 •JAB-21822Glecirasib KRAS G12C GlecirasibKRASG12CSHP2EGFRglecirasib(PK)MiratiKRASG12C oNSCLC ≥2L NSCLC KRAS G12Cglecirasib I800QDRP2D40800QD≥2L NSCLCIIa40glecirasib34TRAE23%5TRAEKRASG12CTRAE Glecirasib≥2LNSCLC(cORR)42.5%(17/40)(DCR)95%(38/40)(mPFS)9.6 KRASG12C≥2LNSCLC60202392024NDACMC20239CDENDA20243Glecirasib≥2L NSCLC KRAS G12CNDA2024CDE 202212glecirasibCDEKRASG12CNSCLC 1L NSCLCJAB-3312 GlecirasibJAB-3312KRASG12CI/IIa1442023102023ESMOGlecirasib+JAB-331234TRAE39.6%glecirasib 800QD+JAB-3312 2[1/1]36.7%5TRAEglecirasibJAB-3312NSCLCORR65.5%(38/58)DCR100%glecirasib800QD+JAB-3312 2[1/1]ORR86.7%(13/15)DCR100%mPFS 200KRASG12CglecirasibJAB-33121001LNSCLC2024ASCO PD-1+glecirasibJAB-33121LNSCLCCDE20242glecirasibJAB-33121LNSCLCIIIIII2024JAB-3312IIISHP2 oPDAC 20237glecirasibKRASG12CPDACCDE20239202310gleciraisb≥2LKRAS G2C 20238glecirasibCDEKRAS G12CCDE GlecirasibIIIa2024ASCOGI2024131PDACglecirasib≥2LPDAC(cORR)41.9%(13/31)(DCR)93.5%(29/31)(mPFS)5.6(mOS)10.7 GlecirasibPDAC20244glecirasibFDA EGFRcetuximab I/IIaglecirasibKRAS G12C 35glecirasib 800QDKRAS G12Cglecirasib2023JCA-AACR2023529(ORR)33.3% (11/33)(DCR)90.9% (30/33)(mPFS)6.9 I/IIaglecirasibcetuximabKRAS G12C I/IIa202322023247CRCglecirasib800QDcetuximab2023JCA-AACR2023529glecirasibcetuximabORR62.8%(27/43)DCR93%(40/43)mPFSTRAEs1-2 GlecirasibglecirasibcetuximabCRCCDE2024CDE cetuximab o KRASG12CglecirasibGlecirasibIIIa202412024(ASCO)GI19glecirasibORR57.9%(11/19)DCR84.2%(16/19)mPFS7.0mOS12OS58.2% oSTK 11 I/IIaKRASG12CSTK11NSCLC o GlecirasibI20228II20229 18A.08(3)glecirasib •JAB-3312 JAB-3312SHP2RASSHP2SHP2SHP2 SHP220185FDAINDSHP2JAB-3312SHP2SHP2JAB-3312IC500.7-3.0 nMIII2QDJAB-3312FDA JAB-3312 JAB-3312KRAS G12CEGFRPD-1 JAB-3312KRAS G12C JAB-21822GlecirasibKRAS G12C– NSCLC – 1L NSCLCJAB-3312 JAB-3312 JAB-3312osimertinibPD-1JAB-3312 18A.08(3)JAB-3312 •JAB-8263 JAB-8263BETc-MycJAB-8263BETBRD2BRD3BRD4BRDTIC500.200.99 nMJAB-826380-90%c-Myc48JAB-8263MFAMLJAB-8263BETJAB-8263(TSS)(SVR) JAB-8263II2024JAB-82632024 18A.08(3)JAB-8263 •JAB-2485 JAB-2485AuroraAAuroraARBJAB-2485AuroraAAuroraBCJAB-2485AuroraAAuroraBAuroraC1500JAB-2485PKAurora A JAB-2485I/IIa20231RP2D2024 JAB-2485202342023AACR2023AACR 18A.08(3)JAB-2485 •JAB-30355 JAB-30355p53 Y220Cp53 JAB-30355p53Y220Cp53 Y220Cp53 Y220CCDXPDXJAB-30355PK JAB-30355IND20243FDAJAB-30355CDEINDI2024IIJAB-30355JAB-30355 2024AACR 18A.08(3)JAB-30355 •JAB-BX102 J